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Available online 6 May 2016Cholangiocarcinoma (CCA) is the primary cancer of the bile duct system. The role of bile duct tissuemicrobiomes
in CCA tumorigenesis is unestablished. To address this, sixty primary CCA tumors and matched normals, from
both liver ﬂuke (Opisthorchis viverrini) associated (OVa, n = 28) and non-O. viverrini associated (non-OVa,
n = 32) cancers, were proﬁled using high-throughput 16S rRNA sequencing. A distinct, tissue-speciﬁc
microbiome dominated by the bacterial families Dietziaceae, Pseudomonadaceae and Oxalobacteraceae was ob-
served in bile duct tissues. Systemic perturbation of themicrobiomewas noted in tumor and paired normal sam-
ples (vs non-cancer normals) for several bacterial familieswith a signiﬁcant increase in Stenotrophomonas species
distinguishing tumors vs paired normals. Comparison of parasite associated (OVa) vs non-associated (non-OVa)
groups identiﬁed enrichment for speciﬁc enteric bacteria (Biﬁdobacteriaceae, Enterobacteriaceae and
Enterococcaceae). One of the enriched families, Biﬁdobacteriaceae, was found to be dominant in the O. viverrini
microbiome, providing a mechanistic link to the parasite. Functional analysis and comparison of CCA
microbiomes revealed higher potential for producing bile acids and ammonia in OVa tissues, linking the altered
microbiota to carcinogenesis. These results deﬁne how the unique microbial communities resident in the bile
duct, parasitic infections and the tissue microenvironment can inﬂuence each other, and contribute to cancer.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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Cholangiocarcinoma (CCA) is a tumor thatmanifests from themalig-
nant transformation and uncontrolled proliferation of biliary tree epi-
thelial cells known as cholangiocytes (Lazaridis and Gores, 2005).
Currently, CCA patients have poor prognosis and therapeutic options
have limited efﬁcacy. CCA incidenceﬂuctuates according to varying geo-
graphical regions where underlying risk factors differ (Tyson and El-
Serag, 2011). Strikingly, there can be a large variation in incidence
rates even among different regions in the same country. In northeastthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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CCA, incidence rates can reach as high as 85 in 100,000 (Bragazzi et
al., 2012). In comparison, the north, central and south of Thailand
have much lower CCA incidence rates at 14.6/100,000, 14.4/100,000
and 5.7/100,000 respectively, correlating with the prevalence of liver
ﬂuke (Opisthorchis viverrini) infection in the region (Bragazzi et al.,
2012). On the other hand, choledochal cysts, hepatolithiasis and prima-
ry sclerosing cholangitis are the main risk factors for CCA in locations
where liver ﬂuke parasitism is not prevalent (Tyson and El-Serag,
2011). Although the clinical risk factors for CCA have been clearly delin-
eated, the molecular mechanisms underlying the different risk factors
for CCA development still remain unclear (Fava, 2010).
The interaction of microbes with host cells is known to have amajor
impact on the health of the host (Hooper et al., 2012; Kau et al., 2011)
and has been implicated in diseases ranging from metabolic disorder
(Qin et al., 2012) to cancer (Schwabe and Jobin, 2013; Sobhani et al.,
2011; Nagarajan et al., 2012). Speciﬁcally, there is an increasing interest
in understanding the role of the tissue microbiome in carcinogenesis,
with extensive work primarily in the area of colon cancer (Kostic et
al., 2013; Kostic et al., 2012). The bile duct is an important component
of the digestive system carrying bile ﬂuids from the liver and gall blad-
der to the intestine. Despite the bile duct's proximity to the largemicro-
bial reservoir in the gastrointestinal tract, and its susceptibility to
microbial infection (Carpenter, 1998), surprisingly little is known
about the human bile duct microbiome (Brook, 1989; Olsson et al.,
1998) and its association with CCA. This could partly be attributed to
technical difﬁculties in the acquisition of a large enough cohort (CCA
is a relatively rare cancer) and in proﬁling microbial abundances from
small biopsies with low bacterial load (Lluch et al., 2015).
To comprehensively characterize the bile duct tissue microbiome,
131 samples were proﬁled using 16S rRNA sequencing, including 60
tumor-normal pairs from CCA patients and 11 control samples (bile
ﬂuids, gastric and hepatic tissue). Bile duct tissueswere observed to har-
bor a distinct microbiome, compared to bile ﬂuids, gastric and hepatic
tissues, dominated by the bacterial families Dietziaceae,
Pseudomonadaceae and Oxalobacteraceae. Unlike in colorectal cancer,
CCA cases exhibited a shared systemic perturbation in both tumor and
adjacent normal tissues, with signiﬁcant focal tumor vs normal differ-
ences restricted to opportunistic pathogens from the genus
Stenotrophomonas. Distinct mutational patterns in liver ﬂuke associated
and non-associated CCA were previously observed (Chan-On et al.,
2013; Ong et al., 2012), linked to their underlying etiologies and risk fac-
tors. To understand the contribution of the tissue microbiome, CCA pa-
tients from both liver ﬂuke (O. viverrini) associated (OVa group, n=28)
and non-O. viverrini associated (non-OVa group, n = 32) groups were
proﬁled. Comparison across groups revealed the enrichment of enteric
bacteria belonging to the families Biﬁdobacteriaceae, Enterobacteriaceae
and Enterococcaceae, some of which could have been directly intro-
duced into the bile duct by the parasite. Inference of functional capaci-
ties of CCA microbiomes revealed a higher potential for producing bile
acids and ammonia in OVa tissues, linking the alteredmicrobiota to car-
cinogenesis (Debruyne et al., 2001; Tsujii et al., 1992).
2. Materials and Methods
2.1. Clinical Specimens
Sixty primary tumor and adjacent matched normal samples (non-
neoplastic liver) were obtained from the Singhealth Tissue Repository
(Singapore), Srinagarind Hospital Khon Kaen University (Thailand)
and the Fundeni Clinical Institute (Romania). Selected samples were
subjected to pathology review to conﬁrm that matched normal samples
did not contain tumor cells. All samples were collected with signed in-
formed consent from patients and study approved by SingHealth Cen-
tralized Institutional Review Board (2006/449/B and 2008/456/B),
NHG Domain Speciﬁc Review Board (2000/00329), Ethics Committeeof the Clinical Institute of Digestive Diseases and Liver Transplantation
Fundeni (215/18.01.2010) and Human Research Ethics Committee at
Khon Kaen University (HE471214). Five non-cancer hepatic tissues
and two bile ﬂuid samples were obtained from the NUHS Tissue repos-
itory. Four non-cancer gastric mucosa samples were collected under a
study approved by NHG Domain Speciﬁc Review Board (Ref: 2000/
00329). Clinicopathological information for subjects including age, gen-
der, ancestry and tumor subtypewas reviewed retrospectively (Supple-
mentary File 1).
2.2. DNA Extraction
Tissue samples were thawed on ice andwere transferred into Lysing
Matrix E tubes (MPBiomedicals, Solon, U.S.A.). A volumeof 650 μl of ATL
Buffer (Qiagen, Hilden, Germany) was added to each sample. Biliary
ﬂuid samples were ﬁrst centrifuged at 8000g for 15 min at 4 °C. The su-
pernatant was discarded and 650 μl of ATL Buffer was added to re-sus-
pend the cell pellet before transferring into Lysing Matrix E tubes.
Both tissue and bile ﬂuid samples were then subjected to bead-beating
with FastPrep-24 Instrument (MP Biomedicals, Solon, U.S.A.) at a speed
of 6.0 m/s for 70 s. Following that, the samples were centrifuged at
16,000g for 5 min and 30 μl of Proteinase K (Qiagen, Hilden, Germany)
was added to the supernatant. Samples were then incubated at 56 °C
for 15 min. Isolation of DNA was carried out using the EZ1 DNA Tissue
Kit (Qiagen, Hilden, Germany) alongwith the automated EZ1 Advanced
XL Instrument (Qiagen, Hilden, Germany). Puriﬁed DNAwas quantiﬁed
with Qubit dsDNA HS Assay Kit (Life Technologies, Eugene, U.S.A.) and
stored at−20 °C.
2.3. 16S rRNA Gene Ampliﬁcation
16S rRNA polymerase chain reaction (PCR) ampliﬁcation was per-
formed as previously described (Ong et al., 2013). Brieﬂy, two hundred
nanograms of extracted DNA was ampliﬁed using primers that target
the V3 to V6 region of the 16S rRNA gene. The primer sequences that
were used for 16S rRNA PCR ampliﬁcation are 338_F: ACT CCT ACG
GGA GGC WGC and 1061_R: CRR CAC GAG CTG ACG AC. HotStar
HiFidelity Polymerase Kit (Qiagen, Hilden, Germany) was used for PCR
and was performed according to the manufacturer's manual except for
a modiﬁcation in primer concentrations (0.5 μM) and the addition of
MgSO4 at a ﬁnal concentration of 2mM. PCRwas set upwith the follow-
ing conditions: Initial denaturation at 95 °C for 5min, followed by 35 cy-
cles of denaturation at 95 °C for 30 s, annealing at 59 °C for 30 s and
extension at 72 °C for 1 min. Lastly, PCR was completed with a step of
ﬁnal extension at 72 °C for 6 min. Agencourt AMPure XP (Beckman
Coulter, Brea, U.S.A.) was used to purify the ampliﬁed products and pu-
riﬁed products were visualized using Agilent Bioanalyzer, prepared
with Agilent High Sensitivity DNA Kit (Agilent Technologies,
Waldbronn, Germany). As controls for assay speciﬁcity, 16S rRNA PCR
was performed with extraction controls and the absence of ampliﬁca-
tion products was conﬁrmed using Agilent Bioanalyzer.
2.4. Library Construction
A standardized amount of 500 ng of PCR product was subjected to
shearing using Adaptive Focused Acoustics™ (Covaris, Woburn,
U.S.A.). Fragment sizes ranged from 100 to 400 bp. DNA libraries were
built using Gene Read DNA Library I Core Kit (Qiagen, Hilden, Germany)
andwere processed according to themanufacturer's protocol except for
using barcode adaptors in place of the recommended adapter set. DNA
libraries were enriched using custom index-primers that would tag
each sample with an index. The enrichment protocol was adapted
from Multiplexing Sample Preparation Oligonucleotide kit (Illumina,
San Diego, U.S.A.). Quantiﬁcation of libraries was carried out using
Agilent Bioanalyzer, prepared with Agilent High Sensitivity DNA Kit
(Agilent Technologies, Waldbronn, Germany). An Illumina HiSeq2000
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2 × 75 bp reads) on all DNA libraries built.
2.5. Preprocessing of Sequencing Reads and 16S rRNA Proﬁling
Sequenced baseswere trimmed off at the 3′ ends of reads, starting at
bases with quality scores b 3. Only read pairs with both reads longer
than 60 bp were kept. 16S reads were identiﬁed by mapping them to
the 16S rRNA database (Pruesse et al., 2007) provided in EMIRGE
(Miller et al., 2011) using BWA-MEM (Li and Durbin, 2009) and with
default parameters (0.7.9a). A mapping was considered valid only if at
least 80% of the bases matched in at least one of the reads in a pair.
Read mappings were used to determine relative abundance of taxa as
previously described (Ong et al., 2013). Brieﬂy, EMIRGE (Miller et al.,
2011), a probabilistic expectation-maximization based algorithm, was
used to reconstruct and measure the abundances of the 16S rRNA se-
quences. The reconstructed sequences were then taxonomically classi-
ﬁed by using BLAST to compare them to the NR database. The
distribution of the number of 16S sequencing reads available for the
samples in the cohort is detailed in Supplementary Fig. 1.
2.6. Computing Diversity Metrics
Shannon diversity index (H) is a metric commonly used in ecology
for measuring the diversity of a community. For each sample we calcu-
lated the Shannon diversity index given as H ¼−∑Ni¼1 pi lnpi using a
custom R script where N is the number of families in each sample and
pi is the relative proportion of a speciﬁc family i. Yue-Clayton theta (θ)
index (Yue and Clayton, 2005) was used for quantifying similarity
across microbiomes. The index was also calculated with a custom R
script using the formula,θ ¼ ∑ipi qi
∑iðpi−qiÞ2þ∑ipiqi
, where pi and qi are relative
proportions of a speciﬁc family i, in sample p and sample q respectively.
Distances between microbial communities was computed using
weighted and unweighted UniFrac distances (Lozupone and Knight,
2005) and tested for statistical signiﬁcance with the Adonis test script
in QIIME (Caporaso et al., 2010).
2.7. Assessing Differential Abundance of Bacterial Taxa
The non-parameteric Wilcoxon rank sum test (for unpaired sam-
ples) and the Wilcoxon signed rank test (for paired samples) were
used to test for differences in bacterial abundance. Correction for multi-
ple hypothesis testing was done by computing false discovery rates
using the R function “p.adjust”. Bacterial taxa with mean abundance
lower than 0.5% (across all samples) were excluded from differential
abundance analysis.
2.8. Whole Metagenome Proﬁling of the Liver Fluke Microbiome
Liver ﬂuke genomic reads were obtained from a previous study
(Young et al., 2014) (pool of N 10 ﬂukes). Sequencing reads were
preprocessed using the NGS QC Toolkit (Patel and Jain, 2012) (version
2.2.3, default parameters) to ﬁlter contamination from Illumina read
adaptors (keeping only pairs where both reads were unﬁltered). The
liver ﬂukemicrobiomewas then proﬁled using the programMetaPhlAn
(Segata et al., 2012) (default parameters) with the ﬁltered reads.
2.9. Microbiome Functional Analysis
We used the program PICRUSt (Langille et al., 2013) (version 1.0.0)
to predict functional metagenomic content from the 16S marker gene
data. Speciﬁcally, the EMIRGE (Miller et al., 2011) reconstructed
amplicon sequences and abundances were converted to QIIME
(Caporaso et al., 2010) format and each amplicon sequence was dupli-
cated according to relative abundances reported by EMIRGE.We pickedOTUs at 90% similarity (between the genus and family identity thresh-
old (Yarza et al., 2014)) against Greengenes (McDonald et al., 2012) ref-
erence OTUs (gg_13_5_otus.tar.gz, provided along with the PICRUSt
package) with QIIME's pick_closed_reference_otus.py script (version
1.8), following the closed reference OTU picking protocol. The output
OTU table was then normalized by 16S copy numbers with PICRUSt's
normalize_by_copy_number.py script. The ﬁnal metagenome predic-
tion was produced using PICRUSt's predict_metagenomes.py script.
The predicted gene abundances were analyzed using HUMAnN
(Abubucker et al., 2012) (version 0.99) to estimate pathway abun-
dances. Differential abundance testing was performed using the
Wilcoxon rank-sum test.
2.10. Data Deposition
All 16S rRNA sequencing reads are available from the NCBI short
read archive (SRA) under the bioproject number PRJNA297250. Liver
ﬂuke genomic reads (Young et al., 2014) are available from run ID
SRR2529483.
3. Results
3.1. Diversity and Distinctness of Human Bile Duct Tissue Microbiome in
CCA Patients
The bacterial families, Dietziaceae, Pseudomonadaceae and
Oxalobacteraceaewere found to be themajor inhabitants of bile duct tis-
sues in CCA patients (Fig. 1a; showing 4 representative OVa and non-
OVa proﬁles). Pseudomonadaceae and Oxalobacteraceae have previously
been reported to be dominant in the penis foreskin microbiome (Price
et al., 2010). Dietzia are metabolically versatile and were previously
found in the human skin and oral microbiome (Dewhirst et al., 2010;
Koerner et al., 2009). Comparing the hepatic tissue microbiome of
non-CCA subjects (n = 5) with bile duct tissue microbiomes (from
CCA patients; n= 60) revealed several shared families (e.g. Dietziaceae,
Pseudomonadaceae and Oxalobacteraceae; Fig. 1b). This is consistent
with the fact that part of the biliary tree is embedded within the liver.
In contrast, gastric mucosal tissue microbiomes (n = 4) were found to
be clearly distinct from bile duct tissue microbiomes (Adonis test p-
value = 0.001 for unweighted and weighted UniFrac distances) and
dominated by Moraxellaceae, with lower abundances of
Burkholderiaceae (Fig. 1c). These ﬁndings are consistent with current
culture-based understanding of these tissues: Pseudomonas species
have been frequently isolated from bile samples (Elomari et al., 1997;
Sutter, 1968) while Acinetobacter species (Moraxellaceae family) have
been reported to colonize gastric tissue and cause gastritis
(Rathinavelu et al., 2003). Analysis of bile ﬂuid samples (n=2) showed
thatwhile Pseudomonadaceaewas themainmicrobial component, there
was substantial variability between the two samples, high diversity in
one sample and a composition that deviates notably from bile duct
(n = 60; Adonis test p-value = 0.001 and 0.009 for unweighted and
weighted UniFrac distances, respectively) and liver tissue microbiomes
(n = 5; Adonis test p-value = 0.044 and 0.001 for unweighted and
weighted UniFrac distances, respectively; Fig. 1d and e). These observa-
tions indicate that bileﬂuidsmay not be a reliable proxy for studying the
resident microbiome of bile duct tissues, though further studies with
matched samples are needed to conﬁrm this. Overall, bile duct tumor
tissue microbiomes from CCA patients exhibited substantial variability
but clustered with adjacent normals, and were distinct from gastric tis-
sues microbiomes (Fig. 1e; Supplementary Fig. 2).
3.2. Enrichment of Speciﬁc Bacterial Taxa and Their Association With CCA
Etiology
Microbiome compositional differences in CCA were investigated
based on 16S rRNA proﬁling on paired tumor-normal tissues for 32
Fig. 1. Tissuemicrobiome 16S rRNAproﬁles of the bile duct, gastricmucosa and liver. Barplots showingmicrobiome proﬁles of (a) bile duct tissue (4 out of 28OVa and4 out of 32non-OVa)
from CCA patients, (b) non-cancer hepatic tissue (n= 5), (c) non-cancer gastric mucosa (n= 4) and (d) bile ﬂuid (n= 2) fromCCA patients at family level resolution. Only familieswith
mean relative abundance N0.5% are shown. (e) Principle coordinates analysis based on Jensen-Shannon distance of themicrobiome proﬁles (family level) of different tissue types (OVa:O.
viverrini associated tissue).
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ed (OVa group) CCA patients (Supplementary File 1 and Supplementary
Figs. 3 and 4). The non-OVa and OVa groups were approximately
matched for age (mean = 56.6 vs 57.9), gender (15 out of 32 male vs
19 out of 28 male) and anatomical subtype (8 out of 32 extra-hepatic
vs 8 out of 28 extra-hepatic) but not for ethnicity (non-thai vs thai; Sup-
plementary File 1). Intra patient (tumor vs normal)microbiomeproﬁles
were found to be more similar relative to inter-tumor (across patient)
microbiome proﬁles (OVa group p-value = 3.8 × 10−07; non-OVa
group p-value = 9.6 × 10−05; Fig. 2a). This suggests the existence of
an individual-speciﬁc tissue microbiome that is either robust to malig-
nant transformation or the result of systemic alterations in both tumor
and adjacent normal (hepatic) tissue. This pattern is also reﬂected in
similar tissue microbiome diversity between paired tumor and normal
tissues (Fig. 2b). However, an increase in microbial diversity in OVa vs
non-OVa subjects was observed (p-value = 0.026 for normal tissue;
Fig. 2b), indicating that O. viverrini infection associates with an altered
microbiome in the bile duct.
Comparison of microbiome proﬁles for normal hepatic tissues from
non-CCA patients (n = 5) with adjacent normal (hepatic) tissues in
CCA patients (n= 60) showed statistically signiﬁcant differences (Ado-
nis test p-value = 0.001 and 0.004 for unweighted and weighted
UniFrac distances, respectively (OVa; n = 28); Adonis test p-value =
0.003 and 0.023 for unweighted and weighted UniFrac distances, re-
spectively (non-OVA; n = 32)), in support of the existence of systemic
microbiomealterations in CCA patients. At the bacterial family level, sig-
niﬁcant differences were observed for Enterobacteriaceae (FDR adjusted
p-value =0.048 (non-OVa)) and Lachnospiraceae (FDR adjusted p-
value = 0.048 (non-OVa)) with borderline signiﬁcance for two other
families (Sphingomonadaceae, Biﬁdobacteriaceae; Supplementary Fig.
5). Enterobacteriaceae is a family of gram-negative bacteria that includesmany pathogens found in the digestive tract (e.g. Klebsiella, Salmonella
and Escherichia coli), while Lachnospiraceae is a family of anaerobic bac-
teria that are frequently found in the human gut.
Despite the systemic impact on the community, speciﬁc bacteria
may colonize differently in tumor vs adjacent normal tissues in CCA pa-
tients. A comparison across all proﬁled bacterial genera revealed a single
genus (Stenotrophomonas, Xanthomonadaceae family), to be signiﬁcant-
ly enriched in tumor vs adjacent normal for non-OVa patients (FDR ad-
justed p-value = 0.039; Supplementary Fig. 6). Interestingly,
Stenotrophomonas has been previously implicated in bile duct infections
(Perez et al., 2014). Notably, Stenotrophomonaswas not found to signif-
icantly differ in abundance in tumor vs adjacent normal tissues for the
OVa group (Supplementary Fig. 6), reﬂecting the distinct etiologies of
the two groups.
For the OVa group, there was no signiﬁcant enrichment or depletion
in bacterial taxa between tumor and adjacent normal tissues (n = 28;
Adonis test p-value = 0.599 and 0.711 for unweighted and weighted
UniFrac distances, respectively). However, comparing OVa vs non-OVa
tissue showed signiﬁcant differences (Adonis test p-value = 0.001 for
unweighted UniFrac distance) and enrichment for Biﬁdobacteriaceae
(FDR adjusted p-value = 5.91 × 10−6 for adjacent normal tissues and
7.80 × 10−7 for tumors), Enterobacteriaceae (FDR adjusted p-value =
0.028 for adjacent normal tissues and 0.0058 for tumors) and
Enterococcaceae (with borderline signiﬁcance; FDR adjusted p-
value = 0.060 for adjacent normal tissues and 0.056 for tumors with
Fisher's combined p-value = 0.02; Fig. 2c). The enrichment was excep-
tionally strong for Biﬁdobacteriaceae (a family of anaerobic bacteria that
is frequently found in the gut, vagina and oral microbiota), which was
detected in 41 (out of 56 adjacent normal and tumor) OVa samples vs
5 (out of 64 adjacent normal and tumor) non-OVa samples. Since
these bacteria are enriched in both adjacent normal and tumor tissues,
Fig. 2. Comparison of O. viverrini associated and non-associated paired tumor-normal tissuemicrobiomes. (a) Boxplots of Yue-Clayton theta indices for quantifying similarity across tissue
microbiomes (family level) within tumor-normal pairs, for O. viverrini associated (n = 28; OVa) tumors and non-O. viverrini associated (n = 32; non-OVa) tumors respectively. (b)
Boxplots depicting the microbiome diversity of O. viverrini associated and non-associated tumor and adjacent normal tissues. (c) Boxplots showing the relative abundance of the 3
families identiﬁed to be enriched in O. viverrini associated (n = 28) vs non-O. viverrini (n = 32) associated tissues. All p-values were calculated using the Wilcoxon rank-sum test,
where ***, ** and * represent FDR adjusted p-values b 0.01, 0.05 and 0.1 respectively.
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through a distal acting mechanism unlike that for Fusobacteriumwhich
is closely associated with colorectal tumor tissue (Kostic et al., 2012).
3.3. Biﬁdobacteriaceae Is the Dominant Member of the O. viverrini
Microbiome
Based on the increased microbial diversity in O. viverrini associated
tissues (Fig. 2b), a working hypothesis is that the introduction of novel
microbes into bile duct tissues could be a consequence of O. viverrini
parasitism. To explore this, reads originating from bacterial species in
a previous O. viverrini shotgun sequencing study (pool of ﬂukes from
an animal model of opisthorchiasis) were examined to reconstruct the
O. viverrinimicrobiome (Young et al., 2014). Notably, Biﬁdobacteriaceae,
the bacterial family that is highly enriched in O. viverrini associated bile
duct tissues (Fig. 2c), was found as the main component of the O.
viverrinimicrobiome (Fig. 3). However, for the other two bacterial fam-
ilies (Enterobacteriaceae and Enterococcaceae) whichwere also enriched
in OVa group tissues, we noted that they were either at very low abun-
dances (Enterobacteriaceae) or not detectable at our threshold
(Enterococcaceae) in the O. viverrinimicrobiome (Fig. 3). These results
suggest that additional factors could have contributed to their enrich-
ment in OVa group tissues.
3.4. Metabolic Pathways Enriched in O. viverrini Associated Tissue
Microbiomes Are Linked to Tumorigenesis
The metabolic output of the microbiome can directly impact tumor-
igenesis (Louis et al., 2014; Swartz et al., 2012). To evaluate if this is thecase in CCA, pathway abundances for tissue microbiomes were recon-
structed and assessed based on their 16S rRNA proﬁles (see Materials
and Methods). These were then compared between OVa and non-OVa
tissuemicrobiomes to determine their functional differences. Strikingly,
amino acidmetabolism pathways (Arginine and Proline; Glycine, Serine
and Threonine) emerged as the two enriched pathways in OVa vs non-
OVa tissue microbiomes (mirroring recent studies showing glycine de-
pendency in tumor-initiating cells (Zhang et al., 2012)), while genes
in the phosphotransferase system and oxidative phosphorylation path-
ways were enriched in non-OVa tissue microbiomes vs their OVa coun-
terparts (Fig. 4a). Pathways enriched in non-OVa tissue microbiomes
are key for energy production and understanding their functional impli-
cations for carcinogenesis would require further investigation.
Biﬁdobacteriaceae, Enterobacteriaceae and Enterococcaceae, shown
earlier to be enriched in OVa tissue microbiomes, are known constitu-
ents of the gut microbiome (Fei and Zhao, 2013; Kostic et al., 2015;
Matsuki et al., 1999). Metabolic activities of speciﬁc gut microbiota are
known to result in the formation of carcinogens such as ammonia and
bile acids (Fig. 4b),which have been implicated in colorectal cancer pro-
gression (Louis et al., 2014). The analysis of enriched microbial path-
ways points to a similar role for the tissue microbiome in O. viverrini
associated CCA development. Speciﬁcally, the enrichment of amino
acid metabolism pathways in the OVa tissue microbiome also increases
its potential to generate ammonia as a side product (Fig. 4a). This was
accompanied by signiﬁcantly higher predicted (Langille et al., 2013)
abundance of bile salt hydrolases (BSH) (p-value= 0.007 in normal tis-
sue and p-value = 0.003 in tumor tissues) in OVa vs non-OVa tissue
microbiomes (Fig. 4c). BSH is an important enzyme that is produced
by gut bacteria to break down bile salts into primary bile acids which
Fig. 3. Composition of theO. viverrinimicrobiome based onwholemetagenome proﬁling. Breakdown of the composition of theO. viverrinimicrobiome at family, genus and species levels.
Only members with N 0.5% abundance are shown.
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been previously shown to lead toDNAdamage in host cells, culminating
in carcinogenesis (Yoshimoto et al., 2013). Together, these results pro-
vide a link between the altered microbiome in OVa tissues and its con-
tribution to tumorigenesis.
4. Discussion
Until recently, many internal organswere believed to be sterile envi-
ronments. Recent studies have however changed that view, showing
that even healthy placentas consistently harbor microbial communities
(Aagaard et al., 2014). This study serves to shed light on the complexFig. 4. Functional analysis of the O. viverrini associated tissuemicrobiome. (a) Functional pathw
pairs) andnon-associated (n=32pairs) CCA tissuemicrobiomes. (b) Breakdownof bile salts int
the bsh gene in respective tissue microbiomes (OVa, n = 28; non-OVa, n = 32). All p-values wmicrobial communities’ resident in parts of the hepatobiliary system.
Crosstalk between these communities and those in the intestine could
be mediated by the process of enterohepatic circulation, inﬂuencing
key processes in the host such as nutrient acquisition and drug metab-
olism (Yip et al., unpublished).
Tumormicroenvironment, deﬁned as the assortment of host andmi-
crobial cells associatedwith tumors, is known to be critical in regulating
carcinogenesis (Swartz et al., 2012). There has been increasing evidence
that supports a role for microbiota in shaping the microenvironment
through its metabolic output and interaction with host cells (Louis et
al., 2014; Swartz et al., 2012). The biliary system is prone tomicrobial in-
fections (Carpenter, 1998) and the interactions between bacteria andays that were identiﬁed to be differentially abundant in the O. viverrini associated (n= 28
ometabolic products implicated in carcinogenesis. (c) Boxplots of predicted abundances of
ere calculated using the Wilcoxon rank-sum test.
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tle is known about the biliary tissue microbiome and its contribution to
bile duct tumorigenesis. Description of the biliary tissuemicrobiomehas
been typically generalized from results originating from bile ﬂuid cul-
tures and may not be reﬂective of the biliary tissue microenvironment.
This study serves to shed light on the role of the bile duct tissue
microbiome in CCA development based on extensive 16S rRNA proﬁling
of O. viverrini associated and non-associated paired tumor-normal tis-
sues. To the best of our knowledge, this is the ﬁrst study to proﬁle
tumor and adjacent normal tissue microbiomes of the biliary tree and
serves to further our understanding of the diversity and functional ca-
pacity of the resident community, complementing earlier studies that
used bile ﬂuids or unmatched samples (Aviles-Jimenez et al., 2016;
Wu et al., 2013).
Overall, we found systemic differences in tumor and adjacent nor-
mal CCA tissue microbiomes compared to normal hepatic tissue, but
limited divergence in paired tumor vs normal microbiomes. In fact, O.
viverrini associated tissues did not exhibit any signiﬁcant microbiome
alterations between tumor-normal pairs. The systemic alterations in
CCA tissue microbiomes suggest that the tumor and tissue-resident
microbiomes inﬂuence each other using far-acting mechanisms. For
non-O. viverrini associated tissue samples, the genus Stenotrophomonas
was found to be more abundant in tumor tissue. This is similar to the
distribution proﬁle for Fusobacterium in colorectal carcinoma (Kostic
et al., 2012). Stenotrophomonas is known to be involved in bile duct in-
fections (Perez et al., 2014) and shown to elicit proinﬂammatory cyto-
kine production in vitro (Roscetto et al., 2015). Furthermore, CCA
development has been strongly linked to an inﬂammatory phenotype
(Sia et al., 2013). Consequently, an inﬂammation mediated mechanism
tying the enrichment of Stenotrophomonas to non-OVa CCA tumorigen-
esis deserves further investigation.
Compared to non-OVa tissues, there was notable enrichment of spe-
ciﬁc enteric microbes such as Biﬁdobacteriaceae and Enterobacteriaceae
in the OVa tissue microbiome. Biﬁdobacteriaceae was also seen as the
major constituent of theO. viverrinimicrobiome (with Enterobacteriace-
ae at much lower abundance), providing a link between O. viverrini in-
fection and CCA tissue microbiome alteration in humans, and
extending on previous ﬁndings based on rodent models (Plieskatt et
al., 2013). As O. viverrini infection in humans requires the consumption
of infected raw ﬁsh, we hypothesize that it triggers the observed
microbiome alterations and not vice versa. While an earlier study de-
tected the presence of Helicobacter pylori in the bile of liver ﬂuke infect-
ed CCA patients (Boonyanugomol et al., 2012), we did not detect H.
pylori in our tissue samples, possibly due to the transient nature of
bile ﬂuids and their differences in comparison to bile duct tissue
microbiomes as noted in this study.
Enteric bacteria have been implicated in cancer progression of the
gut (Louis et al., 2014; Schwabe and Jobin, 2013). Their increased abun-
dance in bile duct tissues could promote tumorigenesis in a similar
manner. Indeed, thedata in this study supports an increase in themicro-
bial production of carcinogens such as bile acids (Yoshimoto et al.,
2013) and ammonia (Louis et al., 2014) in the altered microbiome of
OVa tissues. On the basis of these results, we propose a model involving
(i) O. viverrini mediated introduction of speciﬁc enteric microbes into
the bile duct, (ii) subsequent alterations in the metabolic output of
bile duct tissue microbiomes, and (iii) increased levels of potentially
carcinogenic metabolites, culminating in a tissue microenvironment
primed towards malignant transformation. Recent data from a work
that found elevated levels of bile acids in CCA patients, lends further
support to this model (Jusakul et al., 2012). A recent study (Sivan et
al., 2015) demonstrated a role for gut-dwellingBiﬁdobacteria in promot-
ing systemic antitumor immunity. Further studies are thus needed to
evaluate the role of increased Biﬁdobacteria in bile duct tissues with re-
spect to OVa carcinogenesis.
Apart from O. viverrini, Opisthorchis felineus and sinensis Clonorchis
are also known to infect the biliary tract. Indeed, C. sinensis infection isknown as a risk factor for CCA (Tyson and El-Serag, 2011). Comparing
microbiome alterations in biliary tissues associated with O. viverrini
and C. sinensis infections could further clarify the commonalities and
role of the biliary tissue microbiome in parasite-associated CCA.
Our study demonstrates thatmicrobiomes of internal human organs
are highly variable in composition but specialized to their respective
distinct niches. The biological reciprocity between the human host
and the tissuemicrobiome can inﬂuence the regulation of speciﬁc phys-
iological processes. Taken together, the data in this study supports the
notion that compositional shifts in the tissuemicrobiome following par-
asite infection can enable an altered microenvironment to drive tumor-
igenesis. Indeed, Bongers et al. (Bongers et al., 2014) and others have
shown tumor development to be sustained by the crosstalk between
the genetics of the host and the corresponding speciﬁc microbiome.
The results in this work provide observational evidence for this model
but further functional work is needed in the context of CCA carcinogen-
esis. In addition, as the study pools data from three different countries,
other confounding clinical or epidemiological factors (such as the origin
of OVa CCA samples in Thailand) could explain observed difference in
OVa vs non-OVa CCA microbiomes. Additional samples from other re-
gions of the world and an integrated approach that combines informa-
tion about host genetics (e.g. by sequencing the tumor genome),
functional output (e.g. from proteomics and metabonomics) and envi-
ronmental factors (e.g. microbiome proﬁling) is thus likely needed to
dissect host and microbiome contributions to tumorigenesis.
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